Cigna shares jump on reports of abandoned Humana buyout, plans for $10 billion stock buyback

Cigna shares jump on reports of abandoned Humana buyout, plans for  billion stock buyback


Sopa Images | Lightrocket | Getty Images

Shares of Cigna jumped Monday following reports that the health-care giant has scrapped its plans to buy rival Humana due to disagreements on price, putting an early end to what would have been one of the largest deals of the decade.

Cigna late Sunday also announced plans to buy back $10 billion worth of shares, bringing its total planned repurchases to $11.3 billion. The company said in a release that it will consider smaller, “bolt-on” acquisitions in the near term, but did not confirm the reports about its abandoned pursuit of Humana.

Cigna’s stock popped about 17% Monday morning, while Humana’s stock was down more than 1%.  

Spokespeople for Cigna and Humana did not immediately respond to CNBC’s requests for comment on the called-off merger, which was first reported by The Wall Street Journal on Sunday. 

Cigna and Humana couldn’t agree on price and other financial terms of the deal, which would have created a health-care conglomerate with a value exceeding $140 billion, sources familiar with the matter told the Journal. 

That tie-up would have likely attracted fierce antitrust scrutiny. Shares of the companies fell sharply in late November after the Journal first reported that they were discussing a merger. 

But Cigna continues to believe in the merits of a tie-up with Humana, the Journal reported Sunday. The combined company would have been focused on improving access to care and lowering costs for consumers, sources told the Journal.

Jefferies analyst David Windley upgraded shares of Cigna to buy from hold in a Sunday research note, saying the abandoned Humana deal is a “short-term win” for Cigna investors. 

He added that “taking advantage of a negative reaction to deal reports” by announcing its stock buyback plan on Sunday is “music” to Cigna shareholders’ “value-sensitive ears.” 

Windley noted that shares of Cigna have been down sharply since Nov. 6, when reports emerged about the company exploring a sale of its Medicare Advantage business, which manages government health insurance for people age 65 and older. 

Investors interpreted that potential sale as a “step to reduce its antitrust exposure in a deal to acquire” Humana, Windley said.



Source

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 
Health

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 

The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications. Omada plans to expand the offerings under its weight management program as its membership grows […]

Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Health

Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage

U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming […]

Read More
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
Health

Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 

Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients […]

Read More